Results 101 to 110 of about 584,870 (306)

Vaccination-Challenge Trials in Beagle Dogs Using Whole-Cell Leptospira interrogans Serovar Copenhageni Vaccine: Prevention of Clinical Leptospirosis, Serological, Leptospiremia, Leptospiruria, Cytokines, Hematological, and Pathological Changes

Pathogens
A killed, whole-cell vaccine was produced to induce immunity in dogs against leptospirosis. The vaccine, containing serovar Copenhageni, was produced and administered to 12 beagle dogs at both 8 and 12 weeks of age.
Teola Noel, Rod Suepaul, Abiodun A. Adesiyun   +2 more
doaj   +1 more source

Monitoring of circulating tumor DNA allows early detection of disease relapse in patients with operable breast cancer

Molecular Oncology, EarlyView.
Monitoring circulating tumor DNA (ctDNA) in patients with operable breast cancer can reveal disease relapse earlier than radiology in a subset of patients. The failure to detect ctDNA in some patients with recurrent disease suggests that ctDNA could serve as a supplement to other monitoring approaches.
Kristin Løge Aanestad, Marie Austdal, Oddmund Nordgård, Gunnar Mellgren, Satu Oltedal, Marie L. Austbø, Ylva H. Vignes, Thomas Helland, Kristin Jonsdottir, Tone H. Lende, Emilius A. M. Janssen, Bjørnar Gilje, Kjersti Tjensvoll, PBCB study group, Gunnar Mellgren, Tone Hoel Lende, Anette Heie, Kristin Viste, Anita Røyneberg Alvheim, Emiel AM Janssen, Kristin Jonsdottir, Ann Cathrine Kroksveen, Thomas Helland, Einar Gudlaugsson, Oddmund Nordgård, Satu Oltedal, Kristin Løge Aanestad, Jan Terje Kvaløy, Kirsten Lode, Kari Britt Hagen, Marie Austdal, Ylva H. Vignes, Siri Tungland Sola, Nina Egeland Amundsen, Finn Magnus Eliassen, Emeritus Ernst A Lien   +35 more
wiley   +1 more source

Biallelic Inactivation of NSD1 Associated With Carcinogenesis in Sotos Syndrome

Pediatric Blood &Cancer, EarlyView.
Nicholas A. Borja, Anuja Sule, Katie Ann McMullen, Aditi Dhir, Matthew D. Hall, Heather J. McCrea, Sakir Humayun Gultekin, Mustafa Tekin, Bradley Gampel   +8 more
wiley   +1 more source

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

The Danish National Chronic Lymphocytic Leukemia Registry

Clinical Epidemiology, 2016
Caspar da Cunha-Bang,1 Christian Hartmann Geisler,2 Lisbeth Enggaard,3 Christian Bjørn Poulsen,4 Peter de Nully Brown,2 Henrik Frederiksen,5 Olav Jonas Bergmann,6 Elisa Jacobsen Pulczynski,7 Robert Schou Pedersen,8 Linda Højberg Nielsen,9 ...
da Cunha-Bang C, Geisler CH, Enggaard L, Poulsen CB, de Nully Brown P, Frederiksen H, Bergmann OJ, Pulczynski EJ, Pedersen RS, Nielsen LH, Christiansen I, Niemann CU   +11 more
doaj  

The “added value” of enrolling hematological patients in clinical trials: a single-center experience

Frontiers in Hematology
Pharmaceutical expenditure is constantly growing, in parallel with the increasing incidence of cancers and drug development costs. Enrolling patients in clinical trials provides countless advantages both for patients and the healthcare system; the ...
Stefano Loiacono, Elisa Lucchini, Maria Chiara Rossetti, Clara Palmieri, Irina Cebulec, Riccardo Provasi, Martina Lena, Eleonora De Bellis, Chiara Roni, Francesco Zaja, Francesco Zaja   +10 more
doaj   +1 more source

The Clinical Genetics of Hemophilia B (Factor IX Deficiency)

The Application of Clinical Genetics, 2021
Connie H Miller1,2 1Division of Blood Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA, USA; 2Synergy America, Inc., Duluth, GA, USACorrespondence: Connie H MillerDivision
Miller CH
doaj  

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source

Editorial: Women in Science—Hematology 2021

Frontiers in Medicine, 2022
Eleni Gavriilaki, Chien-Ling Huang, Lalitha Nayak   +2 more
doaj   +1 more source

Relationship between HMGB1 and PAI-1 after allogeneic hematopoietic stem cell transplantation

Journal of Blood Medicine, 2016
Shosaku Nomura,1 Yoshinobu Maeda,2 Kazuyoshi Ishii,1 Yuta Katayama,3 Hideo Yagi,4 Naoto Fujishima,5 Shuichi Ota,6 Masato Moriyama,7 Takayuki Ikezoe,8 Yasuhiko Miyazaki,9 Kunio Hayashi,10 Shinya Fujita,1 Atsushi Satake,1 Tomoki Ito,1 Taiichi Kyo,3 Mitsune
Nomura S, Maeda Y, Ishii K, Katayama Y, Yagi H, Fujishima N, Ota S, Moriyama M, Ikezoe T, Miyazaki Y, Hayashi K, Fujita S, Satake A, Ito T, Kyo T, Tanimoto M   +15 more
doaj